生物制剂改善病情抗风湿药对中轴型脊柱关节炎达标缓解的系统评价与荟萃分析
该系统评价与荟萃分析纳入22项随机对照试验及28项长期扩展研究,评估生物制剂DMARDs在中轴型脊柱关节炎中达到ASAS-PR和/或ASDAS-ID的疗效。TNF抑制剂在12至28周多个时间点显示疗效,ASAS-PR率16-62%,ASDAS-ID率24-40%;IL-17A抑制剂第16周ASAS-PR率15-21%,ASDAS-ID率11-16%。荟萃分析显示达到缓解的相对风险为3.864(95%CI 2.937, 5.085)。
要点
- TNF抑制剂在12-28周可使16-62%患者达ASAS-PR,24-40%达ASDAS-ID
- IL-17A抑制剂第16周ASAS-PR率15-21%,ASDAS-ID率11-16%
- 荟萃分析示bDMARDs达ASAS-PR的相对风险为3.864(95%CI 2.937, 5.085)
核心结论
- bDMARDs对以ASAS-PR评估的中轴型脊柱关节炎缓解有明确影响,但缓解样结局的报告仍需改进。
研究设计与样本
- 系统文献综述检索MEDLINE数据库(首次检索2018年5月,更新至2020年2月),纳入随机对照试验及长期扩展研究。
- 共筛选155篇文献,最终纳入22项随机对照试验和28项长期扩展研究。
主要发现
- ASAS-PR是主要使用的缓解样定义。
- TNF抑制剂:14/17项随机对照试验在不同时间点(12、16、24、28周)提供达缓解疗效证据,ASAS-PR率16-62%,ASDAS-ID率24-40%。
- IL-17A抑制剂:研究数量有限,第16周ASAS-PR率15-21%,ASDAS-ID率11-16%。
关键数值与推荐
- 针对ASAS-PR的荟萃分析纳入疗程相似(12、16或24周)的随机对照试验,达缓解的相对风险为3.864(95%CI 2.937, 5.085)。
临床怎么用
- 生物制剂DMARDs可用于中轴型脊柱关节炎患者以达到ASAS-PR定义的缓解,临床决策可参考不同药物类别的缓解率数据。
局限性
- IL-17A抑制剂相关研究数量有限。
- 缓解样结局的报告存在未满足需求,需改进报告标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the efficacy of biologic DMARDs (bDMARDs) in achieving Assessment of Spondyloarthritis International Society partial remission (ASAS-PR) and/or Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS-ID), as remission-like surrogates, in axial SpA (axSpA). METHODS: Data from randomized controlled trials (RCTs), including long-term extensions, were included. A systematic literature review was performed using the MEDLINE database (first search May 2018, updated February 2020) and PICO criteria according to Patients-adults with radiographic or non-radiographic axSpA; Intervention-any bDMARD; Comparator-placebo and/or any different drug; Outcomes-ASAS-PR and/or ASDAS-ID as primary or secondary endpoints. Meta-analysis was performed after assessment of the homogeneity of study designs, populations and outcomes. RESULTS: After screening 155 references, a total of 22 RCTs and 28 long-term extensions were retrieved. ASAS-PR was the dominant remission-like definition used. Concerning TNF inhibitors, 14/17 RCTs provided evidence of efficacy in reaching remission at different time points: 12, 16, 24 and 28 weeks (ASAS-PR in 16-62% of patients and ASDAS-ID in 24-40% of patients). With a limited number of studies available, IL-17A inhibitors exhibited remission rates of 15-21% for ASAS-PR and 11-16% for ASDAS-ID at week 16. A meta-analysis regarding ASAS-PR was performed considering RCTs with a similar duration (12, 16 or 24 weeks). The relative risk for achieving remission was 3.864 (95% CI 2.937, 5.085). CONCLUSION: bDMARDs have a clear impact in axSpA remission evaluated by ASAS-PR. Nevertheless, these data show an unmet need for improved reporting of remission-like outcomes.
引用
- Cruz-Machado AR, Rodrigues-Manica S, Silva JL, et al. Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis. Rheumatology (Oxford). 2020. PMID: 32696064. doi:10.1093/rheumatology/keaa268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。